

**VANCOUVER HOSPITAL & HEALTH SCIENCES CENTRE
CSU PHARMACEUTICAL SCIENCES
DRUG DATA SHEET**

DRUG NAME

Rasburicase

ALTERNATE NAMES

Fasturtec®

MANUFACTURER

Sanofi-Synthelabo

STRENGTH

1.5 mg and 7.5 mg vials

DOSAGE FORM

injection

INDICATIONS

- Recombinant urate-oxidase enzyme used for the treatment and prophylaxis of acute hyperuricaemia in patients with haematological malignancy with high tumor burden and at risk of a rapid tumor lysis or shrinkage at initiation of chemotherapy.
- Criteria for approved rasburicase use are as follows:

1) Hyperuricemia ($\geq 476 \mu\text{mol/L}$)

PLUS

2) ONE of the following hematologic malignancies with high tumor burden:

Burkitt's lymphoma with LDH $> 2 \times \text{ULN}$

Lymphoblastic lymphoma with LDH $> 2 \times \text{ULN}$

Acute T/ B cell lymphoblastic leukemia with WBC $> 50,000/\text{mm}^3$

Acute leukemia with WBC $> 50,000/\text{mm}^3$

PLUS

3) Evidence of tumour lysis, which includes ONE or more of the following:

Potassium $\geq 6.0 \text{ mmol/L}$

Phosphorus $\geq 1.45 \text{ mmol/L}$

Calcium $\leq 1.75 \text{ mmol/L}$

LDH $> 2 \times \text{ULN}$

Creatinine clearance $< 50 \text{ ml/min}$

PLUS

4) Immediate need for chemotherapy (within 72 hours)

OR

Above (1, 2 and 3) PLUS hypersensitivity/allergic reaction to allopurinol

OR

Above (1, 2 and 3) PLUS unable to ingest oral allopurinol

DOSAGE AND ADMINISTRATION

- The manufacturer recommends 0.2 mg/kg/day in 50 mL NS infused over 30 minutes once daily for 5-7 days. A retrospective analysis by Trifilio et al suggested that a single, fixed dose of 3mg infused over 30 minutes appears to be as effective in lowering serum uric acid levels in most patients. An additional 3mg dose can be repeated in 24 hours if necessary. Due to the high cost of this drug, the latter dosing schedule is favored.
- Administered immediately prior to and during the initiation of chemotherapy only; multiple treatment courses cannot be recommended at this time.
- Infuse through a different line than for chemotherapeutic agents or flush with saline between chemotherapeutic infusions and rasburicase.

KNOWN SIDE EFFECTS*

- most common: skin rash (2%)
- less frequently: bronchospasm, nausea and vomiting, haemolysis
- possible production of anti-urate oxidase antibodies

SPECIAL PRECAUTIONS

- Store vials in fridge in original package to protect from light.
- Reconstitute 1.5 mg vials with 1 mL of supplied diluent (concentration = 1.5 mg/mL)
- Reconstitute 7.5 mg vials with 5 mL of supplied diluent (concentration = 1.5 mg/mL)
- Swirl gently. DO NOT SHAKE.
- Reconstituted vials are further diluted in NS to a final volume of 50 mL.
- Prepared infusions should be infused immediately, but are stable for 24 hours in the fridge.
- Incompatible with glucose solutions.

***REPORT ANY ADVERSE DRUG REACTIONS TO THE PHARMACY**